NCT05717062: Broad-spectrum Rapid Antidote: Varespladib IV to Oral Trial for Snakebite (BRAVIO)
- State
- Completed
- Phase
- Phase 2
- People
- 140 taking part
- Started
- 30 May 2023
- Primary completion
- 28 Nov 2024
- Arms
- Varespladib Intravenous Form (IV) + Varespladib Oral tablet (LY315920) + SOC
- Results
- None posted
- 8 Feb 2023: Trial registered
- 30 May 2023: Trial started
- 24 Feb 2025: Trial completed